Ajanta Pharma, a Rs.600 crore pharma entity from Mumbai, has registered strong top line and bottom line growth during the second quarter ended September 2012. Its net profit for the quarter jumped by 84.6 per cent to Rs.21.88 core from Rs.11.85 crore in the same period of last year. Its net sales also moved up 35.9 per cent to Rs.183.68 core from Rs.135.13 crore. With sharp jump in profits, its earnings per share increased to Rs.9.34 from Rs.5.06.

After the announcement of financial performance, Ajanta scrip moved up by over Rs.20 and touched to Rs.407.40 on BSE. The scrip reached at its 52-weeks peak level at Rs.505 on September 21, 2012 as against its lowest level of Rs.145.58 on January 9, 2012.

For the first half ended September 2012, Ajanta's net sales increased by 35.5 per cent to Rs.355.47 crore from Rs.262.44 crore and its net profit up by 70.1 per cent to Rs.41.46 crore from Rs.24.38 crore. EBDITA worked out to Rs.81.10 crore as against Rs.52.47 crore, representing a growth of 55 per cent.